ArticleMedical oncology (Northwood, London, England)2022

OSI-906 restores the sensitivity of ovarian clear cell carcinoma to cisplatin by targeting the IGF1R/AKT pathway.

Li Liu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.